The management of CsA-induced nephropathy and other CsA-evoked side-effects includes therapeutic strategies devoted to minimize its use of replace by other putatively less nephrotoxic drugs, such as Sirolimus, an mTOR inhibitor, as well as to control dyslipidemia and hypertension, usually present. This evidence concerns the gene MTOR and Hypertension.